Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the landscape of leukemia treatment, offering unprecedented opportunities to target and eradicate cancerous cells through genetic engineering. By equipping patients’ T cells with synthetic receptors that recognize specific antigens on leukemia cells, this therapeutic modality enables precise immunological assaults on malignant populations. However, despite its promise, a significant clinical challenge persists: more than half of patients treated with CAR T therapy relapse, undermining long-term efficacy. This attrition is predominantly due to antigen loss or downregulation by leukemia cells, which enables them to evade immune detection and destruction mediated by CAR T cells.
Traditional strategies to overcome antigen escape have focused on the genetic redesign of CAR constructs, aiming to improve targeting breadth or affinity. These approaches, although innovative, are often hampered by their complexity, extended timelines, and high production costs, limiting their scalability and clinical applicability. Recognizing these limitations, researchers at the Institute of Process Engineering (IPE), Chinese Academy of Sciences, have pioneered a novel biomimetic platform that enhances CAR T cell therapeutic efficacy without necessitating further genetic modifications.
This breakthrough platform leverages the biomolecular interaction between ferritin—a naturally occurring iron storage protein—and CD71, a transferrin receptor highly expressed on both leukemia cells and autologous CAR T cells. Through meticulous optimization of solvent conditions and assembly parameters, the researchers engineered a ferritin aggregation cell engager (FACE), designed to self-assemble and function as a molecular bridge. FACE simultaneously binds CD71 on CAR T cells and leukemia cells, thereby reinforcing cellular conjugation and potentiating the immunological synapse critical for target recognition and cytotoxicity.
Extensive validation was performed across multiple preclinical models, including patient-derived xenografts (PDX) with diverse leukemia subtypes and refractory disease phenotypes. FACE-enhanced CAR T cells demonstrated therapeutic equivalence to conventional CAR T cells at only one-fifth the cellular dose, significantly reducing the severity of cytokine release syndrome, a common and life-threatening complication of CAR T therapy. Remarkably, in models harboring leukemia cells with antigen expression diminished to below 10% of baseline, FACE-CAR T cells maintained robust antileukemic activity, achieving 100% survival rates—a feat unattainable by standard CAR T approaches.
Further refinement saw the development of a drug-loaded iteration termed FACED, whereby therapeutic agents are encapsulated within the ferritin’s intrinsic cage-like structure. FACED-CAR T cells exhibited enhanced efficacy against high tumor burdens, including antigen-negative leukemia populations responsible for relapse, by combining targeted cell engagement with localized drug delivery. Such innovations suggest a new paradigm wherein biomolecular scaffolds can augment immunotherapy precision and potency.
The significance of these findings extends beyond their therapeutic impact. The FACE platform employs endogenous proteins and FDA-approved polymer derivatives, ensuring biocompatibility and safety. Its straightforward, scalable manufacturing process enables seamless integration within existing CAR T production workflows as a culture supplement, circumventing the need for additional genetic interventions. This adaptability facilitates rapid clinical translation and broad applicability across diverse hematologic malignancies.
Collaborative efforts with clinical partners at Zhujiang Hospital and the Institute of Hematology & Blood Diseases Hospital facilitated robust analyses of patient samples, confirming the ubiquitous overexpression of CD71 across leukemia variants. An AI-assisted predictive framework developed by the research team further enhances the platform’s translational potential by enabling precision forecasting of FACE-mediated therapeutic improvements, enabling patient-specific tailoring of treatment strategies.
The peer review community has heralded this work as a major advance in the field of adoptive T cell therapies. By directly addressing antigen heterogeneity and treatment resistance without additional genetic manipulation, the FACE approach promises to mitigate key barriers currently limiting CAR T cell efficacy. Its modularity and efficacy in resistant leukemia models position it as a transformative tool for improving patient outcomes.
In summary, this novel biomimetic platform represents a paradigm shift in CAR T therapy for leukemia. Through innovative molecular engineering of cell–cell interfaces and strategic drug delivery, it amplifies therapeutic avidity and circumvents antigen escape. Supported by rigorous in vivo and in vitro validation, this strategy holds substantial promise for improving remission durability in relapsed and refractory leukemia. The work exemplifies the power of integrating biomimicry with immunotherapy to devise clinically relevant and scalable solutions to complex oncological challenges.
As the field advances toward increasingly sophisticated cellular therapies, such biomaterial-based enhancements could usher in a new era of precision immunoengineering. By optimizing the spatial and functional dynamics of immune effector and target cells, researchers can unlock previously inaccessible therapeutic avenues, extending hope to patients confronting aggressive and otherwise intractable hematologic malignancies.
Subject of Research:
Not applicable
Article Title:
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias
News Publication Date:
9-Mar-2026
Web References:
http://dx.doi.org/10.1016/j.cell.2026.02.005
Image Credits:
LI Feng
Keywords:
Leukemia, Blood diseases, Blood cancer, Adoptive T cell therapy, Genetic engineering, Pharmaceuticals
